SuperworthPfizer EPS PFE
Diluted earnings per share by quarter and over the last twelve months, from 2008.
- Last 12 months, to Jun 28, 2026
- $0.76
- Latest quarter, Q2 FY26
- −$0.04
- −108% on a year earlier
- Fiscal year 2025
- $1.36
- −4% on the year before
Pfizer's earnings per share was $0.76 over the twelve months to Jun 28, 2026, down 60% on a year earlier.
In its latest quarter, Q2 FY26, it was −$0.04, down 108% on the same quarter a year before.
Over the five fiscal years to FY2025 it shrank 3% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $1.36 | −4% |
| FY2024 | $1.41 | +292% |
| FY2023 | $0.36 | −93% |
| FY2022 | $5.48 | +42% |
| FY2021 | $3.85 | +144% |
| FY2020 | $1.58 | −45% |
| FY2019 | $2.87 | +54% |
| FY2018 | $1.86 | −47% |
| FY2017 | $3.51 | +200% |
| FY2016 | $1.17 | +5% |
| FY2015 | $1.11 | −22% |
| FY2014 | $1.42 | −55% |
| FY2013 | $3.14 | +61% |
| FY2012 | $1.95 | +52% |
| FY2011 | $1.28 | +24% |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.04 | −108% | $0.76 | |
| Q1 FY26 | $0.47 | −10% | $1.31 | |
| Q4 FY25 | −$0.29 | −514% | $1.36 | |
| Q3 FY25 | $0.62 | −21% | $1.72 | |
| Q2 FY25 | $0.51 | +5000% | $1.88 | |
| Q1 FY25 | $0.52 | −5% | $1.38 | |
| Q4 FY24 | $0.07 | n/a | $1.41 | |
| Q3 FY24 | $0.78 | n/a | $0.74 | |
| Q2 FY24 | $0.01 | −98% | −$0.46 | |
| Q1 FY24 | $0.55 | −43% | −$0.06 | |
| Q4 FY23 | −$0.60 | −169% | $0.36 | |
| Q3 FY23 | −$0.42 | −128% | $1.83 |
Against its peers
Companies in Drug Manufacturers - General nearest Pfizer's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| PFEPfizer | $0.76 | −60% a year |
| GILDGilead Sciences | −$2.67 | −153% a year |
| BMYBristol-Myers Squibb | $4.54 | +83% a year |
| AMGNAmgen | $16.09 | +32% a year |
| MRKMerck | $1.25 | −81% a year |
| ABBVAbbVie | $3.54 | +69% a year |
| JNJJohnson & Johnson | $6.60 | −36% a year |
| BIIBBiogen | $5.65 | −46% a year |
| LLYEli Lilly and | $29.80 | +95% a year |
| Peer median | $5.09 |
Where Pfizer ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Pfizer
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.